Stallergenes Greer Announces Global Agreement With Nestl é Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia ®
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announced today that it has signed global agreements with Nestlé to harness the peanut allergy oral immunotherapy treatment Palforzia®. The transaction was closed upon signing.
Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among children between 2005 and 20152. The difficulty of avoiding peanuts, combined with the severity of allergic reactions, including anaphylaxis, shows the need for effective treatment3.
“We are delighted about this agreement with Nestlé which marks a significant milestone for Stallergenes Greer,” stated Michele Antonelli, CEO of Stallergenes Greer. “Palforzia®, with its robust efficacy and safety profile, is currently the only available approved treatment for inadvertent exposure to peanuts. By entering the food allergy space, Stallergenes Greer becomes the first allergen immunotherapy company to offer both respiratory and food allergy treatments and demonstrates its lasting commitment to provide patients and the medical community with innovative allergen immunotherapy treatments.”
Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer. There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
With this transaction, Stallergenes Greer further strengthens its presence in the field of AIT. The company’s portfolio offers patients and healthcare professionals precise personalised AIT treatments which cover a broad range of administration modes and can be tailored to the individual needs of patients with allergies: sublingual oral solutions, tablets, and injectables for respiratory allergies; and powder to be consumed with semi-solid foods for peanut allergies.
ABOUT PALFORZIA®
Palforzia® is an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy by the U.S. Food and Drug Administration (FDA), the European Commission (EC), the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic. Use of Palforzia® may be continued in patients 18 years of age and older.
Palforzia® is not indicated for the emergency treatment of allergic reactions, including anaphylaxis, and must always be used in conjunction with a peanut-avoidant diet.
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
1 The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247890/. Accessed August 31, 2023
2 Du Toit G, et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med 2015; 372: 803-13. Accessed August 31, 2023.
3 Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230903080283/en/
Contact information
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARMA Instruments Launch Zero Trust G1 Mark II Secure Messaging Communication Device3.10.2023 05:00:00 CEST | Press release
The Russian invasion of Ukraine has ignited an arms race in the theater of cyber warfare. Zero trust is the operative term for military, defense sectors, and governments across the globe. U.S. intelligence agencies and international partners recently published a report warning of the new Russian malware program Sandworm, likely targeting Ukrainian interests in its ongoing war, and U.S. defense agencies set a deadline of 2027 for implementation of zero trust cybersecurity environments [FedTech, August 2023]. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231002887540/en/ Switzerland-based ARMA Instruments AG announces the launch of their ARMA G1 Mark II Secure Messaging Device. Developed with zero trust principles, the device is a closed mobile system for person-to-person messaging at the highest security levels to counter advanced adversary attacks. The device will be beneficial for NGOs, defense agencies, cybersecurity oper
SLB Launches Carbon Storage Screening and Ranking Solution3.10.2023 04:00:00 CEST | Press release
SLB (NYSE: SLB) today launched its carbon storage screening and ranking solution that increases confidence in site selection decisions based on scientific analysis of the long-term integrity and economic potential of an asset. The solution helps customers avoid suboptimal storage sites with risk factors that can waste valuable time and resources as well as decrease the probability of a carbon capture, utilization and storage (CCUS) project reaching final investment decision (FID). “CCUS is one of the most immediate opportunities to reduce emissions, but it must scale up by 100–200 times in less than three decades to have the expected impact on global net zero ambitions,” said Frederik Majkut, senior vice president of Carbon Solutions for SLB’s New Energy business. “Ensuring that a storage site is both safer and economical is crucial for the speed, scale and investment needed to meaningfully drive CCUS growth for a low carbon energy ecosystem.” The screening and ranking solution uses bo
Takeda Provides Update on EXKIVITY ® (mobocertinib)2.10.2023 22:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA towards a voluntary withdrawal of EXKIVITY® (mobocertinib) in the U.S. for adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after platinum-based chemotherapy. Takeda intends to similarly initiate voluntary withdrawal globally where EXKIVITY is approved and is working with regulators in other countries where it is currently available on next steps. This decision was based on the outcome of the Phase 3 EXCLAIM-2 confirmatory trial, which did not meet its primary endpoint and thus did not fulfill the confirmatory data requirements of the Accelerated Approval granted by the U.S. FDA nor the conditional marketing approvals granted in other countries. The EXCLAIM-2 trial was a Phase 3
Galderma announces progress with RelabotulinumtoxinA regulatory submissions2.10.2023 22:27:00 CEST | Press release
Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration (“FDA”). The FDA has issued a Complete Response Letter (“CRL”) to Galderma related to its BLA for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines (frown lines) associated with corrugator and/or procerus muscle activity in adult patients as well as moderate-to-severe lateral canthal lines (crow’s feet) associated with orbicularis oculi muscle activity in adult patients. The CRL points out certain deficiencies isolated to items related to Chemistry, Manufacturing, and Controls (“CMC”) processes. All other aspects of the BLA, including safety and efficacy related parts, did not solicit deficiencies to be addressed. Galderma has already identified changes to the manufacturing process to address feedback. It will also
Visa Launches $100 million Generative AI Ventures Initiative2.10.2023 22:05:00 CEST | Press release
Visa (NYSE: V), a global leader in payments, today announced a new $100 million generative AI ventures initiative to invest in the next generation of companies focused on developing generative AI technologies and applications that will impact the future of commerce and payments. As a pioneer of AI use in payments since 1993, Visa considers this initiative an extension of Visa’s leadership in using AI to drive innovation in payments, create value for partners and clients, and enable and empower global commerce. Generative AI is an emerging subset of AI that is built on Large Language Models (LLMs) to develop artificial general intelligence capable of generating text, images or other content from large sets of existing data when given prompts. “While much of generative AI so far has been focused on tasks and content creation, this technology will soon not only reshape how we live and work, but it will also meaningfully change commerce in ways we need to understand,” said Jack Forestell,